News and FDA-Alerts

The expanded indication makes roflumilast cream 0.3% the first once-daily, steroid-free topical therapy approved for plaque psoriasis in children aged 2 years and older, providing a new long-term treatment option for pediatric patients.

The FDA approved an every-8-week maintenance dosing regimen for Ebglyss (lebrikizumab-lbkz), providing a new administration option for adults and adolescents aged 12 years and older weighing at least 40 kg with moderate-to-severe atopic...

Lysine crotonylation, a post-translational modification previously studied in oncology, may play a role in psoriasis pathogenesis, according to a translational study comparing protein modification profiles in lesional and non-lesional skin.